Slide 1

The Mediterranean School of Oncology 56 th course Breast Cancer: from Epidemiology to Treatment Tunis, November 14, 2008 Slide 2 Consorzio Interuniversitario Nazionale per la Bio-Oncologia The Mediterranean School of Oncology An educational program of: Slide 3 Bologna Chieti-Pescara Ferrara Catanzaro Palermo Roma La Sapienza Napoli Federico II Perugia Ancona Teramo LAquila A Consortium of 15 Italian Universities Foggia Messina Milano Campus Biomedico 32 Full Professors, 55 Associate Professors 95 Scientists 2 Clinical Trial Offices 12.000 sqm laboratories 15 Cancer Clinics www.cinbo.org Tumor Registry & Screening Programs Slide 4 Two classes: 1. Italian residents 2. Foreign students (in English); All courses are accredited for ECM by Ministero della Salute, Italy or/and ESMO Slide 5 2001200320042005 2 4 6 8 10 Courses/year Students/year 200 500 300 400 600 0 0 By December 2007: 47 courses >2500 students 200220062007 Slide 6 Italy Lithuania Jordan USA Turkey Egypt France Spain Iraq Bosnia Israel Russia Polland 15 20 25 30 35 10 Students by country 1954 Belgium Germany Iran 5 78 7572 Slide 7 Molecular pathology & cancer genetics Onco-hemathology Medical oncology Radiation oncology Epidemiology/ biostatistics & clinical trials Cancer prevention & early diagnosis .. A large spectrum of cancer-related disciplines is covered, including: Slide 8 Postgraduate courses; Training courses for health professionals not frequently dealing with cancer patients; Special topics for oncology nurses; Master classes (residential, 2-weeks, with practical workshops) ( Coming soon) Educational program Slide 9 Scholarships Available to candidatesSlide 10 Diapo avaible a partir du 24 novembre prochaine: http://www.mso.cinbo.org/ Slide 11 Slide 12 Bologna Chieti-Pescara Ferrara Catanzaro Palermo Roma La Sapienza Napoli Federico II Perugia Ancona Teramo LAquila A Consortium of 15 Italian Universities Foggia Messina Milano Campus Biomedico Slide 13 2008 Course calendar March 3-4*Digestive cancers: from epidemiology to management March 28-29 Assessing and managing toxicities of molecularly targeted agents April 11-12 Highlights in management of gastrointestinal cancer May 9-10Highlights in the management of prostate cancer June 13-14Highlights in the management of NSCL cancer July 4-5Highlights in the management of breast cancer September 26-27Highlights in management of kidney cancer October 16-18to be defined October 23-26to be defined November 7-8to be defined November 28-29Translational oncology: novel agents, approaches and targets *Cairo, Egypt Slide 14 Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Formazione a Distanza in Oncologia (FADO) Program Slide 15 FADO Program Teaching is made via satellite technology. Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training. Slide 16 Target audience 1. Residents in medical oncology; 2. Ph.D. students (Dottorato di Ricerca) in oncology and related disciplines Consorzio Interuniversitario Nazionale per la Bio-Oncologia Slide 17 FADO - Partners Technologies & services: Organization & management: Slide 18 Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Mediterranean Task Force for Cancer Control (MTCC) Slide 19 courses videoconferences; lectures-seminars-lessons; To provide a forum for distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area MTCC An innovative project to raise awareness about cancer prevention and early detection via satellite technology Slide 20 Algeria Croatia EgyptFranceGreece Italy JordanLebanon LybiaMorocco Portugal SyriaSloveniaSpainTunisiaTurkey Palestine Launching Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection (MTCC) February 2nd, 2007 Rome, Italy With the participation of delegates from: Albania Slide 21 Axel Ullrich Pioneer in signal transduction & cancer research Cloned human insulin gene licensed to Eli Lilly Discovered EGFR, HER2, FLK-1 etc Architect of targeted therapeutics One of the first scientists at Genentech Responsible for Herceptin annual sales ca. >$1.0BN Discoveries led to SUTENT projected sales >$1.0BN Director of Max Planck Society Founder of SUGEN Inc. NASDAQ listed in 1994 Sold to Pharmacia in 1997 for $670m